ArticleMedicine2026
Performance of low-cost noninvasive blood markers of liver cirrhosis in adults with chronic hepatitis B infection with and without comorbid alcohol use in Zambia: A cross-sectional hospital-based study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Diagnosing liver cirrhosis in patients with chronic hepatitis B (CHB) remains challenging due to the infrequent use of biopsy. In low-and-middle-income countries, access to transient elastography (TE), a recommended noninvasive imaging modality for cirrhosis assessment, is limited. It is against this backdrop that we investigated the diagnostic performance of several low-cost and readily accessible blood-based liver fibrosis markers among patients with CHB infection in Zambia. We performed a hospital-based cross-sectional study in Lusaka, Zambia, among consecutive treatment naive adults presenting at the university teaching hospital with CHB mono-infection (i.e., human immunodeficiency virus-negative). The reference test for cirrhosis was TE of ≥9.6 kilopascals. Low-cost markers were the aspartate transaminase-to-platelet ratio index (APRI) at the recommended threshold >2, as well as lower proposed alternative thresholds for Africa, >0.5 and >0.65, aspartate transaminase/alanine transferase ratio, and fibrosis 4 index (FIB-4 index) >3.25. We evaluated the performance of each marker versus TE. In a secondary analysis, we evaluated marker performance in participants with current alcohol use versus lifetime abstinence. A total of 239 adults with HBV mono-infection were included in this analysis. The mean age was 34.7 years. About 22.2% (n = 53) reported current alcohol use. The prevalence of cirrhosis by TE was 16.3% (95% confidence interval: 11.87-21.63). The area under the receiver operating characteristic curve was 0.83, 0.80, 0.79 and 0.73 for FIB-4, APRI >0.5, APRI >0.65, and APRI >2, respectively. Virtually all indices performed less well in people with current alcohol use. These findings suggest the use of a lower APRI threshold in African settings and the use of the FIB-4 index for diagnosing cirrhosis among patients with CHB. The currently recommended APRI threshold may fail to identify some individuals with cirrhosis who would benefit from antiviral treatment. Clinicians using these markers should routinely screen for alcohol use and consider reevaluating cirrhosis status following reductions in alcohol consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.